Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

I4409

Sigma-Aldrich

Fulvestrant

>98% (HPLC)

Synonym(s):

(7α,17β)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol, Faslodex, ICI 182,780, ZD 182780, ZD 9238, ZM 182780

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C32H47F5O3S
CAS Number:
129453-61-8
Molecular Weight:
606.77
MDL number:
MFCD00903953
UNSPSC Code:
51111800
PubChem Substance ID:
329815373
NACRES:
NA.77

Quality Level

100

Assay

>98% (HPLC)

form

powder

solubility

DMSO: >5 mg/mL

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24

InChI

1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1

InChI key

VWUXBMIQPBEWFH-WCCTWKNTSA-N

Gene Information

human ... ESR1(2099) , ESR2(2100)

Looking for similar products? Visit Product Comparison Guide

Application

Fulvestrant has been used:
  • as an antagonist of estrogen receptor (ERα and ERβ) to reduce hepatocytes proliferation
  • as an antagonist of ER for the suppression of estrogen responsive element in human breast cancer MCF-7 cells
  • as anti-estrogen in breast cancer cell lines

Biochem/physiol Actions

Fulvestrant (ICI 182,780) is a selective estrogen receptor down-regulator (SERD). Fulvestrant is a high affinity estrogen receptor antagonist. IC50 = 0.29 nM. Fulvestrant is the first "pure" antiestrogen with no agonistic activity both in vitro and in vivo.
Fulvestrant is a 7α-alkylsulphinyl analog of 17β-oestradiol and is structurally different compared to other selective estrogen receptor (ER) modulators (SERMs). It reduces dimerization and nuclear localization of the estrogen receptor (ER). Fulvestrant lowers the level of ER protein in human breast cancer cells. Fulvestrant is preferred for the treatment of women at their menopause having hormone-sensitive advanced breast cancer.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Hazard Statements

H413

Precautionary Statements

P273

Hazard Classifications

Aquatic Chronic 4

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nuclear Respiratory Factor 1 Acting as an Oncoprotein Drives Estrogen-Induced Breast Carcinogenesis
Das J, et al.
Cells, 7(12), 234-234 (2018)
Glutamic acid ameliorates estrogen deficiency-induced menopausal-like symptoms in ovariectomized mice
Han NR, et al.
Nutrition Research (New York, N.Y.), 35(9), 774-783 (2015)
Partial hepatectomy induces delayed hepatocyte proliferation and normal liver regeneration in ovariectomized mice
Umeda M, et al.
Clinical and Experimental Gastroenterology, 8(2), 175-175 (2015)
Manuele G Muraro et al.
Oncoimmunology, 6(7), e1331798-e1331798 (2017-08-16)
Interaction between cancerous, non-transformed cells, and non-cellular components within the tumor microenvironment plays a key role in response to treatment. However, short-term culture or xenotransplantation of cancer specimens in immunodeficient animals results in dramatic modifications of the tumor microenvironment, thus
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Vergote I and Abram P
Annals of Oncology, 17(2), 200-204 (2005)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service